Related references
Note: Only part of the references are listed.Bevacizumab Does Not Increase the Risk of Remote Relapse in Malignant Glioma
Antje Wick et al.
ANNALS OF NEUROLOGY (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Concurrent Radiotherapy and Temozolomide Followed by Temozolomide and Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme
John D. Hainsworth et al.
CANCER (2010)
Phase 2 Trial of Talampanel, a Glutamate Receptor Inhibitor, for Adults With Recurrent Malignant Gliomas
Fabio M. Iwamoto et al.
CANCER (2010)
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers
C. Powell et al.
CANCER TREATMENT REVIEWS (2010)
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas
Tatsuya Ozawa et al.
GENES & DEVELOPMENT (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
Gregor Dresemann et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
PI3K Signaling in Glioma-Animal Models and Therapeutic Challenges
Christine K. Cheng et al.
BRAIN PATHOLOGY (2009)
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Prognostic Significance of c-Met Expression in Glioblastomas
Doo-Sik Kong et al.
CANCER (2009)
Phase I Pharmacokinetic Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787) Plus Imatinib and Hydroxyurea for Malignant Glioma
David A. Reardon et al.
CANCER (2009)
Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients
Kan V. Lu et al.
CANCER RESEARCH (2009)
A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas
Teri N. Kreisl et al.
CLINICAL CANCER RESEARCH (2009)
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
Tom Mikkelsen et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
Stuart A. Grossman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Michael D. Prados et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
Walid S. Kamoun et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Rechallenge with temozolomide in patients with recurrent gliomas
Antje Wick et al.
JOURNAL OF NEUROLOGY (2009)
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Vanessa Milano et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy
Jinyan Du et al.
NATURE BIOTECHNOLOGY (2009)
Will integrin inhibitors have proangiogenic effects in the clinic?
Michael Weller et al.
NATURE MEDICINE (2009)
Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
Andrew R. Reynolds et al.
NATURE MEDICINE (2009)
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro
Gabriele D. Maurer et al.
NEURO-ONCOLOGY (2009)
Bevacizumab and chemotherapy for recurrent glioblastoma A single-institution experience
P. L. Nghiemphu et al.
NEUROLOGY (2009)
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Andrew S. Chi et al.
ONCOLOGIST (2009)
Yes and PI3K bind CD95 to signal invasion of glioblastoma
Susanne Kleber et al.
CANCER CELL (2008)
Phosphatidylinostol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis
Daniela Opel et al.
CANCER RESEARCH (2008)
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
Michael Brave et al.
CLINICAL CANCER RESEARCH (2008)
Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
Luca Toschi et al.
CLINICAL CANCER RESEARCH (2008)
Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models
Shinji Yamazaki et al.
DRUG METABOLISM AND DISPOSITION (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
Eric Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J. F. de Groot et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL
Johannes Rieger et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Response criteria for glioma
A. Gregory Sorensen et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts
H. Toni Jun et al.
CLINICAL CANCER RESEARCH (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-α and anticancer drugs
In Sup Kil et al.
FREE RADICAL BIOLOGY AND MEDICINE (2007)
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
Annick Desjardins et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Gefitinib in patients with progressive high-grade gliomas:: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
E. Franceschi et al.
BRITISH JOURNAL OF CANCER (2007)
Synergistic antiglioma activity of radiotherapy and enzastaurin
Ghazaleh Tabatabai et al.
ANNALS OF NEUROLOGY (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells
Esther P. Jane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Integrin-regulated FAK-Src signaling in normal and cancer cells
Satyajit K. Mitra et al.
CURRENT OPINION IN CELL BIOLOGY (2006)
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro:: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways
Chunrong Yu et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Characterization of an imatinib-sensitive subset of high-grade human glioma cultures
D. Hagerstrand et al.
ONCOGENE (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
JR Graff et al.
CANCER RESEARCH (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme
RJ Raizer
JOURNAL OF NEURO-ONCOLOGY (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor
M Holdhoff et al.
BLOOD CELLS MOLECULES AND DISEASES (2005)
Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death
JP Steinbach et al.
CANCER RESEARCH (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Adult glioma incidence trends in the United States, 1977-2000
KR Hess et al.
CANCER (2004)
Share Paper
